FAM222A, Part of the BET-Regulated Basal Endothelial Transcriptome, Is a Novel Determinant of Endothelial Biology and Angiogenesis-Brief Report.

Autor:	Tzani A; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Haemmig S; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Cheng HS; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Pérez-Cremades D; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Heuschkel MA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Jamaiyar A; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Singh SA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Aikawa M; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Yu PB; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Wang T; Department of Ophthalmology, Boston Children's Hospital, MA (T.W., Y.S.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Sun Y; Department of Ophthalmology, Boston Children's Hospital, MA (T.W., Y.S.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Feinberg MW; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.)., Plutzky J; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., M.W.F., J.P.).; Harvard Medical School, Boston, MA (A.T., S.H., H.S.C., D.P.-C., M.A.H., A.J., S.A.S., M.A., P.B.Y., T.W., Y.S., M.W.F., J.P.).
Jazyk:	angličtina
Zdroj:	Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2024 Jan; Vol. 44 (1), pp. 143-155. Date of Electronic Publication: 2023 Nov 09.
DOI:	10.1161/ATVBAHA.123.319909
Abstrakt:	Background: BETs (bromodomain and extraterminal domain-containing epigenetic reader proteins), including BRD4 (bromodomain-containing protein 4), orchestrate transcriptional programs induced by pathogenic stimuli, as intensively studied in cardiovascular disease and elsewhere. In endothelial cells (ECs), BRD4 directs induced proinflammatory, proatherosclerotic transcriptional responses; BET inhibitors, like JQ1, repress these effects and decrease atherosclerosis. While BET effects in pathogenic conditions have prompted therapeutic BET inhibitor development, BET action under basal conditions, including ECs, has remained understudied. To understand BET action in basal endothelial transcriptional programs, we first analyzed EC RNA-Seq data in the absence versus presence of JQ1 before using BET regulation to identify novel determinants of EC biology and function. Methods: RNA-Seq datasets of human umbilical vein ECs without and with JQ1 treatment were analyzed. After identifying C12orf34, also known as FAM222A (family with sequence similarity 222 member A), as a previously unreported, basally expressed, potently JQ1-induced EC gene, FAM222A was studied in endothelial and angiogenic responses in vitro using small-interference RNA silencing and lentiviral overexpression, in vitro, ex vivo and in vivo, including aortic sprouting, matrigel plug assays, and murine neonatal oxygen-induced retinopathy. Results: Resting EC RNA-Seq data indicate BETs direct transcriptional programs underlying core endothelial properties including migration, proliferation, and angiogenesis. BET inhibition in resting ECs also significantly induced a subset of mRNAs, including FAM222A-a unique BRD4-regulated gene with no reported EC role. Silencing endothelial FAM222A significantly decreased cellular proliferation, migration, network formation, aorta sprouting, and Matrigel plug vascularization through coordinated modulation of VEGF (vascular endothelial growth factor) and NOTCH mediator expression in vitro, ex vivo, in vivo; lentiviral FAM222A overexpression had opposite effects. In vivo, siFAM222A significantly repressed retinal revascularization in neonatal murine oxygen-induced retinopathy through similar angiogenic signaling modulation. Conclusions: BET control over the basal endothelial transcriptome includes FAM222A, a novel, BRD4-regulated, key determinant of endothelial biology and angiogenesis. Competing Interests: Disclosures None.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu